Estimate Recalculated Nov 11, 2024 01:52PM EST
Matthew L. Kaplan does not have any significant net worth to report based on the numbers we have. This is based on reported shares in Nuvectis Pharma, Inc..
Matthew L. Kaplan's CIK is 0001895952
2022 was Matthew L. Kaplan's most active year for acquiring shares with 3 total transactions. Matthew L. Kaplan's most active month to acquire stocks was the month of April. 2022 saw Matthew L. Kaplan paying a total of $50,632.73 for 18,000 shares, this is the most they've acquired in one year.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!